Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.

Trial Details

NCT ID
NCT06567743
Phase
PHASE2
Sponsor
CG Oncology, Inc.
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Cretostimogene Grenadenorepvec
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Bakersfield, California, United States|35.37329,-119.01871

Key Eligibility Criteria

  • Pathologically confirmed BCG-naïve high-risk high-grade NMIBC (i.e., CIS with or without Ta/T1 disease or high-grade Ta/T1 papillary-only disease w…
  • All visible disease must be resected, and all CIS resected or fulgurated, as feasible within 90 days prior to treatment allocation.
  • Acceptable baseline organ function.
  • Cohort B Key Inclusion Criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →